X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Natco Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs NATCO PHARMA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS NATCO PHARMA IPCA LABS/
NATCO PHARMA
 
P/E (TTM) x 38.8 30.7 126.6% View Chart
P/BV x 3.0 23.2 12.8% View Chart
Dividend Yield % 0.2 0.5 35.0%  

Financials

 IPCA LABS   NATCO PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-17
NATCO PHARMA
Mar-14
IPCA LABS/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs643877 73.3%   
Low Rs503424 118.7%   
Sales per share (Unadj.) Rs254.4223.4 113.9%  
Earnings per share (Unadj.) Rs16.131.1 51.7%  
Cash flow per share (Unadj.) Rs29.840.3 73.9%  
Dividends per share (Unadj.) Rs1.005.00 20.0%  
Dividend yield (eoy) %0.20.8 22.7%  
Book value per share (Unadj.) Rs194.6219.5 88.6%  
Shares outstanding (eoy) m126.2033.07 381.6%   
Bonus/Rights/Conversions -PA-  
Price / Sales ratio x2.32.9 77.4%   
Avg P/E ratio x35.720.9 170.3%  
P/CF ratio (eoy) x19.216.1 119.2%  
Price / Book Value ratio x2.93.0 99.4%  
Dividend payout %6.216.1 38.7%   
Avg Mkt Cap Rs m72,30021,504 336.2%   
No. of employees `00013.3NA-   
Total wages/salary Rs m6,9601,128 617.2%   
Avg. sales/employee Rs Th2,413.5NM-  
Avg. wages/employee Rs Th523.2NM-  
Avg. net profit/employee Rs Th152.4NM-  
INCOME DATA
Net Sales Rs m32,1067,389 434.5%  
Other income Rs m226167 135.1%   
Total revenues Rs m32,3327,556 427.9%   
Gross profit Rs m4,4481,793 248.0%  
Depreciation Rs m1,730304 568.2%   
Interest Rs m241366 65.8%   
Profit before tax Rs m2,7031,290 209.6%   
Minority Interest Rs m046 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m675309 218.7%   
Profit after tax Rs m2,0281,027 197.4%  
Gross profit margin %13.924.3 57.1%  
Effective tax rate %25.023.9 104.4%   
Net profit margin %6.313.9 45.4%  
BALANCE SHEET DATA
Current assets Rs m17,3403,681 471.0%   
Current liabilities Rs m9,5593,123 306.1%   
Net working cap to sales %24.27.6 320.6%  
Current ratio x1.81.2 153.9%  
Inventory Days Days10089 112.1%  
Debtors Days Days5759 96.9%  
Net fixed assets Rs m20,7797,685 270.4%   
Share capital Rs m252331 76.3%   
"Free" reserves Rs m24,4996,670 367.3%   
Net worth Rs m24,5537,259 338.2%   
Long term debt Rs m3,517955 368.4%   
Total assets Rs m39,59511,957 331.1%  
Interest coverage x12.24.5 270.4%   
Debt to equity ratio x0.10.1 108.9%  
Sales to assets ratio x0.80.6 131.2%   
Return on assets %5.711.7 49.2%  
Return on equity %8.314.2 58.4%  
Return on capital %10.520.7 50.6%  
Exports to sales %48.639.4 123.6%   
Imports to sales %14.25.7 249.8%   
Exports (fob) Rs m15,6172,908 537.1%   
Imports (cif) Rs m4,571421 1,085.2%   
Fx inflow Rs m15,6173,445 453.3%   
Fx outflow Rs m5,828703 829.2%   
Net fx Rs m9,7902,743 356.9%   
CASH FLOW
From Operations Rs m2,7641,440 191.9%  
From Investments Rs m-1,432-1,089 131.4%  
From Financial Activity Rs m-1,591-353 451.2%  
Net Cashflow Rs m-259-1 17,369.1%  

Share Holding

Indian Promoters % 45.9 52.0 88.2%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 11.4 7.8 145.4%  
FIIs % 25.3 16.6 152.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 26.0 66.9%  
Shareholders   36,892 25,395 145.3%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   PIRAMAL ENTERPRISES  GSK PHARMA  PANACEA BIOTECH  MERCK LTD  NOVARTIS  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jan 19, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - DR. DATSONS LABS COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS